Original Article

Antibiotics susceptibility of Escherichia coli isolates from clinical specimens before and during COVID-19 pandemic


Background and Objectives: Escherichia coli is a Gram-negative organism causing mild to severe infections, with a wide spectrum range of organs involved. The study aimed to describe antibiotics susceptibility of E. coli from clinical specimens from October 11, 2019 to September 11, 2020.
Materials and Methods: Study was conducted retrospectively in a private microbiology laboratory in Mataram Indonesia. Period of study divided as two groups after WHO declared COVID-19 as pandemic by March 11, 2020; group A including the specimen related to September 2019 to March 11th 2020 and group B including the specimens related to March 11th 2020 to September 2020. All clinical specimens were subjected to identify E. coli isolates and their antibiotics susceptibility using WHO-NET 5.6 version.
Results: Totally, 148 E. coli isolates were found in group A and 62 isolates in group B. Prevalence of extended-spectrum beta lactamase (ESBL)- producing E. coli in group A was 50% and in group B was 20.9% with significantly difference (p<0.05). There was an increase in susceptibility to 10/16 antibiotics; where 3 antibiotics ofloxacin, aztreonam, and fosfomycin were significant (p<0.05). There was a significant decrease in susceptibility to the antibiotics piperacillin (p=0.012), amoxicillin (p=0.002), cefadroxil (p=0.036) and ampicillin (p=0.036). Type of infections between two groups: musculoskeletal infections, pneumonia, urinary tract infections and sepsis were not significant.
Conclusion: Reduced number of E. coli isolates between two groups with decrease of ESBL-producing E. coli contribute in dynamics of antibiotics susceptibility. The longer period of analysis is needed to be done, due to the ongoing COVID-19 pandemic.

1. WHO. Fact sheet Antibiotic Resistance. 2020. Available at https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
2. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 2018;11:1645-1658.
3. CDC. Antibiotic Resistance Threats in the United States 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
4. Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules 2020; 25:1340.
5. Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health 2013;10:6235-6254.
6. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015;40:277-283.
7. McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, et al. Incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: A systematic literature review. Infect Control Hosp Epidemiol 2017; 38:1209-1215.
8. Public Health England (2020). English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) 2015 to 2019.
9. Hadi U, Kuntaman, Qiptiyah M, Paraton H. Problem ofantibiotic use and antimicrobial resistance in Indonesia: are we really making progress? IJTID 2013; 4: 5-8.
10. Hayati Z, Rizal S, Putri R. Isolation of extended-spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumiae from Dr. Zainoel Abidin General Hospital, Aceh. Int J Trop Vet Biomed Res 2019;4:16-22.
11. van Duin D, Barlow G, Nathwani D. The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. JAC Antimicrob Resist 2020; 2: dlaa053.
12. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ 2020;98:442-442A.
13. CLSI (2019). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI Supplement M100. Wayne PA: Clinical and Laboratory Institute.
14. Lee DS, Lee SJ, Choe HS. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int 2018;2018:7656752.
15. Collignon P, Beggs JJ. CON: COVID-19 will not result in increased antimicrobial resistance prevalence. JAC Antimicrob Resist 2020; 2: dlaa051.
16. Clancy CJ, Buehrle DJ, Nguyen MH. PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. JAC Antimicrob Resist 2020; 2: dlaa049.
17. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014; 6: 25-64.
18. Manyi-Loh C, Mamphweli S, Meyer E, Okoh, A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules 2018; 23:795.
19. Kibret M, Abera B. Antimicrobial susceptibility patterns of E. coli from clinical sources in northeast Ethiopia. Afr Health Sci 2011; 11(Suppl 1): S40-S45.
20. Kulkarni SR, Peerapur BV, Sailesh KS. Isolation and antibiotic susceptibility pattern of Escherichia coli from urinary tract infections in a tertiary care hospital of North Eastern Karnataka. J Nat Sci Biol Med 2017; 8:176-180.
IssueVol 13 No 2 (2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v13i2.5974
Antimicrobial resistance; COVID-19 pandemic; Escherichia coli

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Wardoyo E, Suardana IW, Yasa IWP, Sukrama ID. Antibiotics susceptibility of Escherichia coli isolates from clinical specimens before and during COVID-19 pandemic. Iran J Microbiol. 2021;13(2):156-160.